CERV-E

Internal Request: In response to the FDA approval of pembrolizumab for the treatment of advanced cervical cancer with disease progression during or after chemotherapy whose tumors express PD-L1, the panel voted on pembrolizumab for this indication.

External request: Submission from Merck and Co, Inc to add pembrolizumab as a systemic therapeutic option for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.

Panel Discussion/References

Based upon review of the data in the noted reference(s) and the recent FDA approval, the panel consensus was to expand the use of pembrolizumab to include PD-L1-positive tumors. As a result, the second-line therapy option for recurrent or metastatic disease changed from “Pembrolizumab for MSI-H/dMMR tumors (category 2B)” to “Pembrolizumab for PD-L1-positive or MSI-H/dMMR tumors (category 2A)”


Institution Vote

<table>
<thead>
<tr>
<th></th>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERV-E</td>
<td>23</td>
<td>0</td>
<td>1</td>
<td>4</td>
</tr>
</tbody>
</table>